Philosys Healthcare Files Global Patent Application for COVID-19 Diagnostic Kit
[Asia Economy Reporter Hyungsoo Park] Philosis Healthcare announced on the 20th that it has jointly filed a global patent for COVID-19 diagnostic kit-related technology developed together with its affiliate Philosis.
The patent technology improves sensitivity and accuracy by specially treating the surface of the COVID diagnostic kit. Philosis Healthcare and Philosis jointly filed a domestic patent on the 9th.
The global patent application was made through the Patent Cooperation Treaty (PCT) international application. This has the same effect as directly filing patents in 153 PCT member countries.
When filing a PCT international application, patents are simultaneously submitted to 153 member countries. Since it goes through an international phase before entering the national phase, there is a disadvantage in that domestic patent rights cannot be secured early. To prevent this, Philosis Healthcare and Philosis proceed with domestic filing and PCT international filing separately.
A Philosis Healthcare official said, "Overseas export contracts for the COVID-19 diagnostic kit 'Gmate COVID-19,' launched on the 13th, are increasing," adding, "We proceeded with this global patent application to prevent technology disputes during overseas exports."
The COVID-19 diagnostic kit 'Gmate COVID-19' is a product that improved accuracy, which was previously mentioned as a drawback of the conventional immunodiagnostic method, up to 93%. It is rapidly increasing overseas contracts, achieving a cumulative supply contract amount of 18.1 billion KRW just six days after its launch announcement.
Meanwhile, the U.S. Food and Drug Administration (FDA) announced on the 16th (local time) the 'Regulatory Relief Guidelines for Expanding the Use of COVID-19 Diagnostic Kits,' including regulatory easing for immunodiagnostics. It is expected that rapid immunodiagnostic devices using antigens or antibodies can be exported to the United States.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Since Gmate COVID-19 uses an immunodiagnostic method, it takes only 20 minutes to obtain test results and has 93% accuracy, which is not significantly different from molecular diagnostic methods. It uses saliva samples such as nasal mucus and sputum, making specimen collection simple and test results quick. Therefore, it is expected to be highly useful in mobile clinics such as drive-thru testing sites.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
